Acute promyelocytic leukaemia and acquired α-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients

Por Wassenaar, T., Black, J., Kahl, B., Schwartz, B., Longo, W., Mosher, D., Williams, E.
Publicado em 2008

Two Diarylurea Electron Transport Inhibitors Reduce Staphylococcus aureus Hemolytic Activity and Protect Cultured Endothelial Cells from Lysis

Por Proctor, R. A., Dalal, S. C., Kahl, B., Brar, D., Peters, G., Nichols, W. W.
Publicado em 2002

Pharmacodynamic Evaluation of the Activity of Antibiotics against Hemin- and Menadione-Dependent Small-Colony Variants of Staphylococcus aureus in Models of Extracellular (Broth) a...

Por Garcia, L. G., Lemaire, S., Kahl, B. C., Becker, K., Proctor, R. A., Denis, O., Tulkens, P. M., Van Bambeke, F.
Publicado em 2012

A child with soft-tissue infection and lymphadenitis

Por Froböse, N.J., Masjosthusmann, K., Huss, S., Correa-Martinez, C.L., Mellmann, A., Schuler, F., Kahl, B.C., Wittkowski, H., Schaumburg, F.
Publicado no New Microbes New Infect (2020)

The role of body mass index in survival outcome for lymphoma patients: US intergroup experience

Por Hong, F., Habermann, T. M., Gordon, L. I., Hochster, H., Gascoyne, R. D., Morrison, V. A., Fisher, R. I., Bartlett, N. L., Stiff, P. J., Cheson, B. D., Crump, M., Horning, S. J., Kahl, B. S.
Publicado no Ann Oncol (2014)

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

Por Goy, A., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Nasta, S., O'Connor, O. A., Shi, H., Boral, A. L., Fisher, R. I.
Publicado no Ann Oncol (2009)

VcR-CVAD induction chemotherapy followed by maintenance rituximab produces durable remissions in mantle cell lymphoma: a Wisconsin Oncology Network study

Por Chang, J.E., Carmichael, L.L., Kim, K., Peterson, C., Yang, D.T., Traynor, A.M., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N.S., Longo, W.L., Kahl, B.S.
Publicado no Clin Lymphoma Myeloma Leuk (2017)

VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study

Por Chang, J. E., Peterson, C., Choi, S., Eickhoff, J. C., Kim, K., Yang, D. T., Gilbert, L. A., Rogers, E. S., Werndli, J. E., Huie, M. S., McFarland, T. A., Volk, M., Blank, J., Callander, N. S., Longo, W. L., Kahl, B. S.
Publicado em 2011

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C

Por Erbe, A K, Wang, Wei, Grzywacz, B, Ranheim, E A, Hank, J A, Kim, K, Carmichael, L, Seo, S, Mendonca, E A, Song, Y, Hong, F, Gascoyne, R D, Paietta, E, Horning, S H, Kahl, B, Sondel, P M
Publicado em 2013

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for Advanced Hodgkin Lymphoma in the Modern Era

Por Diefenbach, C. S., Li, H., Hong, F., Gordon, L. I., Fisher, R. I., Bartlett, N. L., Crump, M., Gascoyne, R. D., Wagner, H., Stiff, P. J., Cheson, B. D., Stewart, D. A., Kahl, B. S., Friedberg, J. W., Blum, K. A., Habermann, T. M., Tuscano, J. M., Hoppe, R. T., Horning, S. J., Advani, R. H.
Publicado no Br J Haematol (2015)